Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers.
The potential impact of tesamorelin on CYP3A activity was investigated by examining its effect on the pharmacokinetics of simvastatin and ritonavir. In two randomized, two-way crossover studies, subjects were administered 2 mg tesamorelin on Days 1-7 with 80 mg simvastatin or 100 mg ritonavir co-administered on Day 6 (Treatment A), and a single dose of simvastatin or ritonavir alone on Day 6 (Treatment B). Pharmacokinetic samples were collected on Day 6 to measure simvastatin, ritonavir and tesamorelin plasma concentrations. For simvastatin, A/B ratios of least squares geometric means and corresponding 90% confidence intervals (CIs) for AUC0-t , AUC0-inf and Cmax were contained within the usual no effect range of 80-125%. For ritonavir, ratios and 90% CIs for AUCs were within this acceptance range, but the lower CI for Cmax was 74.8%, suggesting a decreased rate of exposure. However, since the A/B ratios for AUCs and Cmax parameters were approximately 90%, these were minor decreases and no dose adjustment of ritonavir is required in the presence of tesamorelin. These studies showed that the impact of tesamorelin on CYP3A activity appears to be minimal, if any. Either medication may be co-administered with tesamorelin in patients without changing their original dosing regimen.
PRACS Institute, Fargo, ND, USA.
Shirley
S
Teng
Theratechnologies Inc., Québec, Canada.
Diane
D
Potvin
Theratechnologies Inc., Québec, Canada.
Jean-Claude
JC
Mamputu
Theratechnologies Inc., Québec, Canada.
Geneviève
G
Vincent
Theratechnologies Inc., Québec, Canada.
Monika
M
Zoltowska
Theratechnologies Inc., Québec, Canada.
Josée
J
Morin
Theratechnologies Inc., Québec, Canada.
Saida
S
Hatimi
Theratechnologies Inc., Québec, Canada.
Sophie-Elise
SE
Michaud
Theratechnologies Inc., Québec, Canada.
Kim
K
High
Learn and Confirm Inc., Québec, Canada.
Murray P
MP
Ducharme
CYP3A; lipodystrophy; ritonavir; simvastatin; tesamorelin